APOLLO: Short Interfering RNA Shows Promise for Reducing Lipoprotein(a)

A single ascending dose of SLN360, a short interfering RNA (siRNA), shows promise in lowering plasma lipoprotein(a) [Lp(a)]concentrations in patients with elevated Lp(a) levels and no known cardiovascular disease, based on results from the phase 1 APOLLO trial presented at ACC.22 and simultaneously published in JAMA.

PACMAN-AMI: Adding Alirocumab to High-Intensity Statin Therapy Significantly Reduces High-Risk Plaques

Compared with placebo, the addition of subcutaneous biweekly alirocumab to high-intensity statin therapy resulted in significantly greater coronary plaque regression in non-infarct-related arteries after 52 weeks in patients with acute myocardial infarction (AMI), based on findings from the PACMAN-AMI trial presented at ACC.22 and simultaneously published in JAMA. However, researchers noted that further studies are needed to understand whether alirocumab improves clinical outcomes in this patient population.

TRANSLATE-TIMI 70: Can Vupanorsen Reduce Non-HDL Cholesterol in Statin-Treated Patients?

Vupanorsen, an antisense oligonucleotide targeting angiopoietin-like 3 (ANGPTL3), reduced non-HDL-C by up to 28% in patients who were already taking statins, according to findings from the TRANSLATE-TIMI 70 trial presented at ACC.22 and simultaneously published in Circulation. Researchers also noted significant reductions in other lipid parameters including triglyceride levels, LDL-C and apolipoprotein B (ApoB) levels.

ADAPT-TAVR: Edoxaban vs. DAPT in Reducing SLT, Cerebral TE After TAVR

In patients without an indication for long-term anticoagulation after successful TAVR, the incidence of subclinical leaflet thrombosis (SLT) was numerically lower – but not statistically significant – with edoxaban than with dual antiplatelet therapy (DAPT), according to findings from the ADAPT-TAVR trial presented at ACC.22 and published in Circulation.

Chocolate Touch Device Superior to Lutonix in Efficacy, Similar in Safety in Patients Undergoing PTA

The second-generation paclitaxel-coated Chocolate Touch device may be superior to the Lutonix drug-coated balloon catheter among patients undergoing percutaneous transluminal angioplasty (PTA) for superficial femoral and popliteal artery disease, according to results from the Chocolate Touch study presented at ACC.22 and simultaneously published in Circulation.